Who Said What about


Multiple people spoke about Amgen in the news. We gather all their quotes on this page, an easy way to see all views about this topic at a glance. To go deeper, all quotes are redirected to the article from which they come. Sean E. Harper is the person who had the greatest number of quotes. The most recent one of them is: “To see a more than 20 percent risk reduction for stroke was really exciting.”.

See more

Read all Sean E. Harper's quotes about Amgen
Read all Marc Sabatine's quotes about Amgen
Read all Steven Nissen's quotes about Amgen
Read all Vasant Narasimhan's quotes about Amgen

All quotes about Amgen

Automatically powered by
Joshua Ofman - Amgen

In fact, they may even be below the value-based range for the types of patients getting access now. We want to engage payers in risk-sharing contracts. If the drug does not perform, net prices will go down. But if the drug performs as we expect, the[...]

Troyen Brennan - CVS Health

I think responsibly, if the number you are treating goes up and you are trying to recoup the cost of (developing) the drug ... one would hope that the price would go down.

Ronny Gal

At a cost of $7K/year, this translates to $958K per event saved. Thus, in our view, payers will continue to restrict access to the drug.

Marc Sabatine

As a society we need to move to modifying these risk factors earlier in life to not only prevent recurrent events but to prevent first events.

Mark Hlatky

That's the biggest issue – whether they're worth all the money.

Marc Sabatine

That's a big benefit.

Sean E. Harper - Amgen

Endeavor is the only (relapsed multiple myeloma) study to demonstrate a survival benefit in a head-to-head comparison with a current standard of care regimen.

Ying Huang

In light of Trump's proposal on cash repatriation, we believe AMGN could repatriate a significant portion of its $34.8B cash held overseas. The potential share buyback, dividend payment and acquisitions associated with the cash repatriation can furt[...]

Richard Francis - Sandoz

[The legal fight] won't really reach a conclusion until 2018. That's the frustration sometimes of the legal situation, but the way I look at that, we're carving the landscape out as we go.

Len Schleifer - Regeneron Pharmaceuticals

To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't beloved.

Len Schleifer - Regeneron Pharmaceuticals

If this industry is to survive, we have got to do the right thing by patients … and still adequately reward our investors.

Len Schliefer

To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't beloved. If this industry is to survive, we have got to do the right thing by patients ... and still adequately reward our investors.

Jim Cramer

I think Amgen can go much higher, perhaps on comments coming out of this healthcare conference.

Michael Yee - RBC Capital Markets

If Praluent was gone from the market the long-term peak sales for Repatha could move from $2 billion to $3 billion to $4 billion worldwide, in theory.

Karen Linehan - Sanofi

We will immediately appeal today's ruling, along with the jury's earlier finding upholding the validity of Amgen's patents. It is our longstanding position that Amgen's patent claims are invalid and that the best interests of patients will be greatl[...]

Ashleigh Koss - Sanofi

It is our longstanding position that Amgen's asserted patent claims are invalid, and we intend to appeal today's ruling.

Kristen Davis - Amgen

The court's ruling today is an important step in this case and confirms the jury's finding that the patents which protect Repatha are valid and infringed by Sanofi.

Randy Shultz

We've got 13 million candidate patients ... and at least initially there will be four drugs addressing what is five times as many patients (as the RA market). We would argue that each of these drugs has the potential to be a blockbuster alongside ea[...]

Charles Duncan - Piper Jaffray

Migraine today can be characterized as similar to RA in the past, in that it's a large but under-treated, and also under-diagnosed, market. The burden of disease in terms of patient quality of life, function, and resource utilization is also high. B[...]

Seth Baum

It's crazy what's going on. They've basically destroyed our capacity to treat our patients with the drugs that we need to treat them with.

Stephen Nicholls

These findings suggest that the large clinical outcome trials currently underway are likely to show major benefits.

Steven Nissen - Cleveland Clinic

That's unbelievable. So when you get down to 24 you've got a really high chance of your plaques melting away.

Steven Nissen - Cleveland Clinic

We saw profound regression.

Michael Nawrath

It's not like these companies are bitter enemies. These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their blockbusters.

Richard Francis - Sandoz

The realization of what it's going to take to stay in this market and be successful has led to a change in the landscape and the players in it.

Andrzej Jakubowiak

This was the wrong combination chosen for this evaluation, wrong duration of treatment as well, which we now know and is potentially important.

Vasant Narasimhan - Novartis

These important data further support the efficacy of AMG 334 in patients who currently have limited therapeutic options.

Carol Lynch - Novartis

We are committed to bringing Erelzi to the U.S. market as soon as possible.

Chad Morganlander

We believe that you're going to see consistent revenue growth, as well as improvement within operating margins over the next three to five years.

David Seaburg - Cowen and Company

We are seeing something occur very different on the desk here. We're seeing people versus selling every rally, or shorting every rally, coming in now and buying every dip. We're seeing a big sentiment shift in general; people getting very comfortabl[...]

Sean E. Harper - Amgen

Migraine is the sixth leading cause of disability worldwide. Three to seven million Americans spend more than half of each month living with the debilitating symptoms of chronic migraine.

Tim Race - Deutsche Bank

A permanent injunction is unlikely. However, the likelihood of settlement has now increased substantially with Sanofi and its partner Regeneron potentially forced to pay royalties.

Jay Siegel

Only direct clinical comparisons of (Remsima) and Remicade in active irritable bowel disease can provide the requisite assurance.

Robert A. Bradway - Amgen

We remain on track to meet or exceed our 2018 commitments and deliver value for patients and shareholders.

No quotes...
More Amgen quotes
|< <
> >|